tbuckley/cabot-search huggingface dataset:
Patient satisfaction with cancer care delivery through telemedicine at a comprehensive cancer center across three years during and after the COVID-19 pandemic.
Authors: Sahil D Doshi, Yasin Khadem Charvadeh, Kenneth Seier, Erin Mary Bange, Robert Michael Daly, Fernanda C. G. Polubriaginof, Michael T. Buckley, Gilad Kuperman, Peter D. Stetson, Deb Schrag, Michael J. Morris, Katherine Panageas
Journal: Journal of Clinical Oncology (2024)

1632 Background: Telemedicine, once sparingly utilized, surged during the COVID-19 pandemic to enhance care accessibility and safety concerns. Despite initial satisfaction, its usage remains highly variable across institutions. We sought to explore patient satisfaction at a comprehensive cancer center, associations with demographic characteristics, and change over time. Methods: A survey was sent to all first-time telemedicine users at Memorial Sloan Kettering Cancer Center from September 2021 to October 2023. Adult patients who had their initial telemedicine visit, regardless of specialty, received the questionnaire. It comprised 10 general questions about the telemedicine experience and 11 questions regarding clinical trial education and informed consent. To analyze the unstructured free text responses, we employed BERTopic, a topic modeling algorithm that leverages transformer-based embeddings to facilitate the creation of easily interpretable topics within a collection of text documents. Through topic modeling with BERT embeddings, we captured subtle nuances and semantic relationships in language to identify topics more effectively. Results: A total of 15,111 patients completed 15,251 questionnaires; 140 patients completing two surveys. Patient demographics are summarized in Table 1; the median age at encounter was 66 years and 98% of patients preferred English. Satisfaction levels were high, with 92% expressing willingness for future telemedicine visits and 90% recommending it to other patients. Notably, 21% found telemedicine superior to in-person visits, while 53% considered them equal. Further, satisfaction remained consistent across six-month intervals from 2021-2023. In 1606 (11%) surveys, patients noted discussing clinical trials; 17% preferred in-person discussions for the informed consent process while most either preferred telemedicine or had no preference. Topic modeling revealed 18 topics within the unstructured dataset; key topics included comments on video &amp; audio quality, connectivity and technology issues, convenience for patients who live outside of the city and those with physical limitations, and long wait time to see a doctor. Conclusions: Our analysis confirms high patient satisfaction with telemedicine, including discussions on clinical trial enrollment, that has remained consistent in the years following the COVID-19 pandemic. Given variability in use, it is important to identify how to better deliver telemedicine to those patients who prefer it.[Table: see text]
To see or not to see: In vivo nanocarrier detection methods in the brain and their challenges
Authors: Antonia Clarissa Wehn, Eva Krestel, Biyan Nathanael Harapan, Andrey Klymchenko, Nikolaus Plesnila, Igor Khalin
Journal: Journal of Controlled Release (2024)

Nanoparticles have a great potential to significantly improve the delivery of therapeutics to the brain and may also be equipped with properties to investigate brain function. The brain, being a highly complex organ shielded by selective barriers, requires its own specialized detection system. However, a significant hurdle to achieve these goals is still the identification of individual nanoparticles within the brain with sufficient cellular, subcellular, and temporal resolution. This review aims to provide a comprehensive summary of the current knowledge on detection systems for tracking nanoparticles across the blood-brain barrier and within the brain. We discuss commonly employed in vivo and ex vivo nanoparticle identification and quantification methods, as well as various imaging modalities able to detect nanoparticles in the brain. Advantages and weaknesses of these modalities as well as the biological factors that must be considered when interpreting results obtained through nanotechnologies are summarized. Finally, we critically evaluate the prevailing limitations of existing technologies and explore potential solutions.
When I use a word . . . The languages of medicines—trade names, proprietary names, or brand-names
Authors: Jeffrey K Aronson
Journal: BMJ (2024)

Individual medicines have both chemical names and generic names, such as British Approved Names (BANs) and International Nonproprietary names (INNs). Medicinal products are often referred to by the generic names of their active ingredients. However, a medicinal product, which contains inactive as well as active ingredients, can also have a proprietary name, also known as a trade name or brand name. The UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued guidance on what is and is not acceptable in the formulation of such proprietary names.
Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studies
Authors: Nicole Bézay, Laura Wagner, Vera Kadlecek, Michaela Obersriebnig, Nina Wressnigg, Romana Hochreiter, Martina Schneider, Katrin Dubischar, Ulla Derhaschnig, Anton Klingler, Julian Larcher-Senn, Susanne Eder-Lingelbach, Wolfgang Bender
Journal: The Lancet Infectious Diseases (2024)
Using network pharmacology to discover potential drugs for hypertrophic scars
Authors: Yi Zhang, Xiu Li, Qian Yu, Xiaoyan Lv, Chen Li, Lianzhao Wang, Yue Liu, Qian Wang, Zhigang Yang, Xin Fu, Ran Xiao
Journal: British Journal of Dermatology (2024)

Abstract Background Hypertrophic scarring is a disease of abnormal skin fibrosis caused by excessive fibroblast proliferation. Existing drugs have not achieved satisfactory therapeutic effects. Objectives To explore the molecular pathogenesis of hypertrophic scars and screen effective drugs for their treatment. Methods Existing human hypertrophic scar RNA sequencing data were utilized to search for hypertrophic scar-related gene modules and key genes through weighted gene co-expression network analysis (WGCNA). Candidate compounds were screened in a compound library. Potential drugs were screened by molecular docking and verified in human hypertrophic scar fibroblasts and a mouse mechanical force hypertrophic scar model. Results WGCNA showed that hypertrophic scar-associated gene modules influence focal adhesion, the transforming growth factor (TGF)-β signalling pathway and other biologic pathways. Integrin β1 (ITGB1) is the hub protein. Among the candidate compounds obtained by computer virtual screening and molecular docking, crizotinib, sorafenib and SU11274 can inhibit the proliferation and migration of human hypertrophic scar fibroblasts and profibrotic gene expression. Crizotinib had the best effect on hypertrophic scar attenuation in mouse models. At the same time, mouse ITGB1 small interfering RNA can also inhibit mouse scar hyperplasia. Conclusions ITGB1 and TGF-β signalling pathways are important for hypertrophic scar formation. Crizotinib could be a potential treatment drug for hypertrophic scars.
Integrated Antigenic and Nucleic Acid Detection in Single Virions and Extracellular Vesicles with Viral Content
Authors: Kim Truc Nguyen, Xilal Y. Rima, Luong T. H. Nguyen, Xinyu Wang, Kwang Joo Kwak, Min Jin Yoon, Hong Li, Chi‐Ling Chiang, Jacob Doon‐Ralls, Kelsey Scherler, Shannon Fallen, Stephanie L. Godfrey, Julie A. Wallick, Setty M. Magaña, Andre F. Palmer, Inyoul Lee, Christopher C. Nunn, Kimberly M. Reeves, Henry G. Kaplan, Jason D. Goldman, James R. Heath, Kai Wang, Preeti Pancholi, L. James Lee, Eduardo Reátegui
Journal: Advanced Healthcare Materials (2024)

Virion-mediated outbreaks are imminent and despite rapid responses, continue to cause adverse symptoms and death. Therefore, tunable, sensitive, high-throughput assays are needed to help diagnose future virion-mediated outbreaks. Herein, it is developed a tunable in situ assay to selectively enrich virions and extracellular vesicles (EVs) and simultaneously detect antigens and nucleic acids at a single-particle resolution. The Biochip Antigen and RNA Assay (BARA) enhanced sensitivities compared to quantitative reverse-transcription polymerase chain reaction (qRT-PCR), enabling the detection of virions in asymptomatic patients, genetic mutations in single virions, and enabling the continued long-term expression of viral RNA in the EV-enriched subpopulation in the plasma of patients with post-acute sequelae of the coronavirus disease of 2019 (COVID-19). BARA revealed highly accurate diagnoses of COVID-19 by simultaneously detecting the spike glycoprotein and nucleocapsid-encoding RNA in saliva and nasopharyngeal swab samples. Altogether, the single-particle detection of antigens and viral RNA provides a tunable framework for the diagnosis, monitoring, and mutation screening of current and future outbreaks.
The Dermatology Life Quality Index as the primary outcome in randomized clinical trials: a systematic review
Authors: Jeffrey R Johns, Jui Vyas, Faraz M Ali, John R Ingram, Sam Salek, Andrew Y Finlay
Journal: British Journal of Dermatology (2024)

Abstract Background Primary endpoint measures in clinical trials are typically measures of disease severity, with patient-reported outcome measures (PROMs) relegated as secondary endpoints. However, validation of some PROMs may be more rigorous than that of disease severity measures, which could provide support for a primary role for PROMs. Objectives This study reports on 24 peer reviewed journal articles that used the Dermatology Life Quality Index (DLQI) as primary outcome, derived from a systematic review of randomized controlled trials (RCTs) utlizing DLQI, covering all diseases and interventions. Methods The study protocol was prospectively published on the PROSPERO database, and the study followed PRISMA guidelines. Searches were made using MEDLINE, The Cochrane Library, Embase, Web of Science, Scopus, CINAHL (EBSCO) and PsycINFO databases and records were combined into an Endnote database. Records were filtered for duplicates and selected based on study inclusion/exclusion criteria. Full-text articles were sourced and data were extracted by two reviewers into a bespoke REDCap database, with a third reviewer adjudicating disagreements. The Jadad scoring method was used to determine risk of bias. Results Of the 3220 publications retrieved from online searching, 457 articles met the eligibility criteria and included 198 587 patients. DLQI scores were used as primary outcomes in 24 (5.3%) of these studies comprising 15 different diseases and 3436 patients. Most study interventions (17 of 24 studies, 68%) were systemic drugs, with biologics (liraglutide, alefacept, secukinumab, ustekinumab, adalimumab) accounting for 5 of 25 pharmacological interventions (20%). Topical treatments comprised 32% (8 studies), whereas nonpharmacological interventions (n = 8) were 24% of the total interventions (N = 33). Three studies used nontraditional medicines. Eight studies were multicentred (33.3%), with trials conducted in at least 14 different countries, and four studies (16.7%) were conducted in multiple countries. The Jadad risk of bias scale showed that bias was uncertain or low, as 87.5% of studies had Jadad scores of ≥ 3. Conclusions This study provides evidence for use of the DLQI as a primary outcome in clinical trials. Researchers and clinicians can use this data to inform decisions about further use of the DLQI as a primary outcome.
Oyster mantle-derived exosomes alleviate osteoporosis by regulating bone homeostasis
Authors: Yuanyuan Hu, Zuoxu Hou, Zhengqi Liu, Xiao Wang, Jintao Zhong, Jinjin Li, Xiaoming Guo, Changshun Ruan, Hongxun Sang, Beiwei Zhu
Journal: Biomaterials (2024)
Interleukin-1 mediated hyperinflammation in XIAP-deficiency is associated with defective autophagy.
Authors: Dilan Dissanayake, Ashkan Firouzabady, Mohammad Massumi, Guillermo A. de Paz Linares, Christian Marshall, Spencer A. Freeman, Ronald M. Laxer, Rae S. M. Yeung
Journal: Blood (2024)
Novel therapeutic approaches in thalassemias, sickle cell disease, and other red cell disorders
Authors: Valeria Maria Pinto, Filippo Mazzi, Lucia De Franceschi
Journal: Blood (2024)

In this last decade, a deeper understanding of the pathophysiology of hereditary red cell disorders and the development of novel classes of pharmacologic agents have provided novel therapeutic approaches to thalassemias, sickle cell disease (SCD), and other red cell disorders. Here, we analyze and discuss the novel therapeutic options according to their targets, taking into consideration the complex process of erythroid differentiation, maturation, and survival of erythrocytes in the peripheral circulation. We focus on active clinical exploratory and confirmatory trials on thalassemias, SCD, and other red cell disorders. Beside β-thalassemia and SCD, we found that the development of new therapeutic strategies has allowed for the design of clinic studies for hereditary red cell disorders still lacking valuable therapeutic alternative such as α-thalassemias, congenital dyserythropoietic anemia, or Diamond-Blackfan anemia. In addition, reduction of heme synthesis, which can be achieved by the repurposed antipsychotic drug bitopertin, might affect not only hematological disorders but multiorgan diseases such as erythropoietic protoporphyria. Finally, our review highlights the current state of therapeutic scenarios, in which multiple indications targeting different red cell disorders are being considered for a single agent. This is a welcome change that will hopefully expand therapeutic option for patients affected by thalassemias, SCD, and other red cell disorders.
Randomized Bendamustine-Rituximab(R) + Bortezomib Induction and R + Lenalidomide Maintenance for Mantle Cell Lymphoma
Authors: Mitchell R. Smith, Opeyemi A. Jegede, Peter Martin, Brian G. Till, Samir S. Parekh, David T. Yang, Eric D. Hsi, Thomas Witzig, Sandeep Dave, David Scott, Curtis Hanson, Lale Kostakoglu Shields, Nizar Abdel-Samad, Carla Casulo, Nancy L. Bartlett, Paolo F. Caimi, Tareq Al Baghdadi, Kristie A. Blum, Mark D. Romer, David J. Inwards, Rachel E. Lerner, Lynne I. Wagner, Richard F. Little, Jonathan W. Friedberg, John P. Leonard, Brad S. Kahl
Journal: Blood (2024)
4D intravital imaging identifies platelets as the predominant cellular procoagulant surface in a mouse hemostasis model
Authors: Abigail Ballard-Kordeliski, Robert H. Lee, Ellen C. O’Shaughnessy, Paul Y. Kim, Summer R. Jones, Rafal Pawlinski, Matthew J. Flick, David S. Paul, Nigel Mackman, David A. Adalsteinsson, Wolfgang Bergmeier
Journal: Blood (2024)
Targeting MYC effector functions in pancreatic cancer by inhibiting the ATPase RUVBL1/2
Authors: Markus Vogt, Nevenka Dudvarski Stankovic, Yiliam Cruz Garcia, Julia Hofstetter, Katharina Schneider, Filiz Kuybu, Theresa Hauck, Bikash Adhikari, Anton Hamann, Yamila Rocca, Lara Grysczyk, Benedikt Martin, Anneli Gebhardt-Wolf, Armin Wiegering, Markus Diefenbacher, Georg Gasteiger, Stefan Knapp, Dieter Saur, Martin Eilers, Mathias Rosenfeldt, Florian Erhard, Seychelle M Vos, Elmar Wolf
Journal: Gut (2024)

Objective The hallmark oncogene MYC drives the progression of most tumours, but direct inhibition of MYC by a small-molecule drug has not reached clinical testing. MYC is a transcription factor that depends on several binding partners to function. We therefore explored the possibility of targeting MYC via its interactome in pancreatic ductal adenocarcinoma (PDAC). Design To identify the most suitable targets among all MYC binding partners, we constructed a targeted shRNA library and performed screens in cultured PDAC cells and tumours in mice. Results Unexpectedly, many MYC binding partners were found to be important for cultured PDAC cells but dispensable in vivo. However, some were also essential for tumours in their natural environment and, among these, the ATPases RUVBL1 and RUVBL2 ranked first. Degradation of RUVBL1 by the auxin-degron system led to the arrest of cultured PDAC cells but not untransformed cells and to complete tumour regression in mice, which was preceded by immune cell infiltration. Mechanistically, RUVBL1 was required for MYC to establish oncogenic and immunoevasive gene expression identifying the RUVBL1/2 complex as a druggable vulnerability in MYC-driven cancer. Conclusion One implication of our study is that PDAC cell dependencies are strongly influenced by the environment, so genetic screens should be performed in vitro and in vivo. Moreover, the auxin-degron system can be applied in a PDAC model, allowing target validation in living mice. Finally, by revealing the nuclear functions of the RUVBL1/2 complex, our study presents a pharmaceutical strategy to render pancreatic cancers potentially susceptible to immunotherapy.
Histone deacetylase inhibition mitigates fibrosis-driven disease progression in recessive dystrophic epidermolysis bullosa
Authors: Alessia Primerano, Emanuela De Domenico, Francesca Cianfarani, Naomi De Luca, Giovanna Floriddia, Massimo Teson, Cristina Cristofoletti, Silvia Cardarelli, Giovanni Luca Scaglione, Enke Baldini, Davide Cangelosi, Paolo Uva, Jonathan Fernando Reinoso Sánchez, Carole Roubaty, Jörn Dengjel, Alexander Nyström, Simona Mastroeni, Salvatore Ulisse, Daniele Castiglia, Teresa Odorisio
Journal: British Journal of Dermatology (2024)

Recessive dystrophic epidermolysis bullosa (RDEB) is a blistering disease caused by mutations in the gene encoding type VII collagen (C7). RDEB is associated with fibrosis, which is responsible for severe complications. The phenotypic variability observed in siblings with RDEB suggests that epigenetic modifications contribute to disease severity. Identifying epigenetic changes may help to uncover molecular mechanisms underlying RDEB pathogenesis and new therapeutic targets.
The impact of irritant challenge on the skin barrier and myeloid-resident immune cells in women who are postmenopausal is modulated by hormone replacement therapy
Authors: Orsolya Kiss, Rajia Bahri, Rachel E B Watson, Chidera Chike, Abigail K Langton, Victoria L Newton, Mike Bell, Christopher E M Griffiths, Silvia Bulfone-Paus, Suzanne M Pilkington
Journal: British Journal of Dermatology (2024)

Sex hormone changes during menopausal transition contribute to declining skin health. However, how menopause and its treatment by hormone replacement therapy (HRT) impact the skin barrier and immune system is unclear.
2023 EULAR classification criteria for hand osteoarthritis
Authors: Ida K Haugen, David T Felson, Abhishek Abhishek, Francis Berenbaum, Sita Bierma-Zeinstra, Krysia S Dziedzic, John James Edwards, Martin Englund, Merete Hermann-Eriksen, Gabriel Herrero-Beaumont, Catherine Hill, Mariko L Ishimori, Helgi Jonsson, Teemu Karjalainen, Ying Ying Leung, Emmanuel Maheu, Christian D Mallen, Michelle Marshall, Rikke H Moe, Roberta Ramonda, Valentin Ritschl, Marco JPF Ritt, Tanja A Stamm, Zoltan Szekanecz, Florus van der Giesen, Lotte A van de Stadt, Coen van der Meulen, Ruth Wittoek, Elsie Greibrokk, Hellen Laheij, Margreet Kloppenburg
Journal: Annals of the Rheumatic Diseases (2024)

The objective of this study is to develop classification criteria for overall hand osteoarthritis (OA), interphalangeal OA and thumb base OA based on self-reported data and radiographic features.
Heme induced loss of renovascular endothelial protein C receptor promotes chronic kidney disease in sickle mice
Authors: Qiyang Chen, Rimi Hazra, Danielle Crosby, Diane Lenhart, Shane C. Lenhart, Paritosh Mondal, Yingze Zhang, Seyed M. Nouraie, Roderick J. Tan, Charles T. Esmon, L. Vijay Mohan Rao, Kang Kim, Samit Ghosh
Journal: Blood (2024)
Verification of reprojected planar images generated from a ring-configured cadmium zinc telluride gamma camera in scintigraphy for diagnosing transthyretin cardiac amyloidosis
Authors: Irma Cerić Andelius, Ragnheidur Fridriksdóttir, David Minarik, Fredrik Hedeer, Anna Stenvall, Elin Trägårdh, Jenny Oddstig
Journal:  (2024)

Non-invasive diagnosis of amyloid transthyretin (ATTR) cardiac amyloidosis using planar scintigraphy and single-photon emission computed tomography-computed tomography (SPECT-CT) with [
Long-term Neurobehavioral and Metabolic Outcomes in Offspring of Mothers With Diabetes During Pregnancy: A Large, Population-Based Cohort Study in Ontario, Canada
Authors: Denice S. Feig, Azmina Artani, Ayesha Asaf, Ping Li, Gillian L. Booth, Baiju R. Shah
Journal: Diabetes Care (2024)

Offspring of women with diabetes are at increased risk of developing neurobehavioral and cardiometabolic disorders, but there is scant evidence regarding the association between glycemic level during pregnancy and these long-term offspring outcomes.
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia
Authors: Andreas Hochhaus, Jianxiang Wang, Dong-Wook Kim, Dennis Dong Hwan Kim, Jiri Mayer, Yeow-Tee Goh, Philipp le Coutre, Naoto Takahashi, Inho Kim, Gabriel Etienne, David Andorsky, Ghayas C Issa, Richard A Larson, Felice Bombaci, Shruti Kapoor, Tracey McCulloch, Kamel Malek, Lillian Yau, Sophie Ifrah, Matthias Hoch, Jorge E Cortes, Timothy P Hughes
Journal: New England Journal of Medicine (2024)

Patients with newly diagnosed chronic myeloid leukemia (CML) need long-term therapy with high efficacy and safety. Asciminib, a BCR::ABL1 inhibitor specifically targeting the ABL myristoyl pocket, may offer better efficacy and safety and fewer side effects than currently available frontline ATP-competitive tyrosine kinase inhibitors (TKIs).
A novel exosome-based multifunctional nanocomposite platform driven by photothermal-controlled release system for repair of skin injury
Authors: Xu Teng, Tao Liu, Guifang Zhao, Yaru Liang, Pengdong Li, Fengjin Li, Qiguang Li, Jiacai Fu, Chengming Zhong, Xiaohui Zou, Linhai Li, Ling Qi
Journal: Journal of Controlled Release (2024)
Impact of Continuous Positive Airway Pressure on Glucose Profiles in Gestational Diabetes: A Pilot Randomized-Controlled Trial
Authors: Joshua Smocot, Andrea Benedetti, Raphieal Newbold, Sara Meltzer, R John Kimoff, Natasha Garfield, Evelyne Rey, Kaberi Dasgupta, Robert Gagnon, Sushmita Pamidi
Journal: American Journal of Respiratory and Critical Care Medicine (2024)

"Impact of Continuous Positive Airway Pressure on Glucose Profiles in Gestational Diabetes: A Pilot Randomized-Controlled Trial." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp.
Skin Pigmentation and Pulse Oximeter Accuracy in the Intensive Care Unit: A Pilot Prospective Study
Authors: Ashraf Fawzy, Harith Ali, Peter H. Dziedzic, Niteesh Potu, Eusebia Calvillo, Sherita H. Golden, Theodore J. Iwashyna, Jose I. Suarez, David N. Hager, Brian T. Garibaldi
Journal: American Journal of Respiratory and Critical Care Medicine (2024)